Controlled trial of nicotine polacrilex gum with supportive measures

Arch Intern Med. 1989 Aug;149(8):1818-21. doi: 10.1001/archinte.1989.00390080080018.

Abstract

In a placebo-controlled, double-blind, 2-year prospective study, 182 smokers were given either nicotine polacrilex gum containing 4 mg of nicotine (n = 92) or a placebo (n = 90). The number of participants abstinent at 2-year follow-up was 41 (44.6%) of 92 in the nicotine group vs 28 (31.1%) of 90 in the placebo group. Abstinence rates for daily nicotine gum users (n = 64) at 12 months and again at 24 months remained 48.4%, as compared with 26.1% and 31.9% for the daily placebo gum users (n = 69). Of participants with a high nicotine-dependence score, those allotted to the nicotine group rather than to the placebo group were 13 times more likely to be abstaining at the 2-year follow-up. Use of nicotine polacrilex gum, therefore, can substantially aid in stopping smoking, particularly among highly dependent smokers.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Chewing Gum*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Ion Exchange Resins / therapeutic use*
  • Male
  • Middle Aged
  • Nicotine / analogs & derivatives*
  • Nicotine / therapeutic use
  • Placebos
  • Polymethacrylic Acids / therapeutic use*
  • Polyvinyls / therapeutic use*
  • Prospective Studies
  • Smoking / therapy*
  • Social Support
  • Substance-Related Disorders / therapy
  • Time Factors
  • Tobacco Use Cessation Devices

Substances

  • Chewing Gum
  • Ion Exchange Resins
  • Placebos
  • Polymethacrylic Acids
  • Polyvinyls
  • Nicotine